Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies - 21/04/20

Doi : 10.1016/j.jaad.2020.02.044

Alan Menter, MD, (Co-Chair) ^a, Joel M. Gelfand, MD, MSCE ^b, Cody Connor, MD ^c, April W. Armstrong, MD, MPH ^d, Kelly M. Cordoro, MD ^e, Dawn M.R. Davis, MD ^f, Boni E. Elewski, MD ^c, Kenneth B. Gordon, MD ^g, Alice B. Gottlieb, MD, PhD ^h, Daniel H. Kaplan, MD, PhD ⁱ, Arthur Kavanaugh, MD ^j, Matthew Kiselica, BA/BS ^k, Dario Kivelevitch, MD ^a, Neil J. Korman, MD, PhD ^l, Daniela Kroshinsky, MD, MPH ^m, Mark Lebwohl, MD ⁿ, Craig L. Leonardi, MD ^o, Jason Lichten, MD ^k, Henry W. Lim, MD ^p, Nehal N. Mehta, MD, MSCE ^q, Amy S. Paller, MD ^r, Sylvia L. Parra, MD ^s, Arun L. Pathy, MD ^t, Elizabeth Farley Prater, MD ^u, Robert S. Rahimi, MD, MSCR ^a, Reena N. Rupani, MD ⁿ, Michael Siegel, PhD ^v, Benjamin Stoff, MD, MA ^w, Bruce E. Strober, MD, PhD ^x,^y, Elliot B. Tapper, MD ^z, Emily B. Wong, MD ^aa, Jashin J. Wu, MD ^bb, Vidhya Hariharan, PhD ^cc,^⁎ , Craig A. Elmets, MD, (Co-Chair) ^c
^a Baylor Scott and White, Dallas, Texas
^b University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
^c University of Alabama, Birmingham, Alabama
^d University of Southern California, Los Angeles, San Francisco
^e Department of Dermatology, University of California, San Francisco School of Medicine, San Diego, California
^f Mayo Clinic, Rochester, Minnesota
^g Medical College of Wisconsin, Milwaukee, Wisconsin
^h Department of Dermatology, Icahn School of Medicine at Mt. Sinai, New York, New York
ⁱ University of Pittsburgh, Pittsburgh, Pennsylvania
^j University of California, San Diego, San Diego, California
^k Patient Advocate, National Psoriasis Foundation, Portland, Oregon
^l University Hospitals Cleveland Medical Center, Cleveland, Ohio
^m Massachusetts General Hospital, Boston, Massachusetts
ⁿ Icahn School of Medicine at Mount Sinai, New York, New York
^o Central Dermatology, St Louis, Missouri
^p Department of Dermatology, Henry Ford Hospital, Detroit, Michigan
^q National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
^r Northwestern University Feinberg School of Medicine, Chicago, Illinois
^s Dermatology and Skin Surgery, Sumter, South Carolina
^t Colorado Permanente Medical Group, Centennial, Colorado
^u University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
^v Pediatric Dermatology Society Alliance
^w Emory University School of Medicine, Atlanta, Georgia
^x Central Connecticut Dermatology, Cromwell, Connecticut
^y Yale University, New Haven, Connecticut
^z Michigan Medicine, University of Michigan, Ann Arbor, Michigan
^aa San Antonio Uniformed Services Health Education Consortium, Joint-Base San Antonio, Texas
^bb Dermatology Research and Education Foundation, Irvine, California
^cc American Academy of Dermatology, Rosemont, Illinois

^∗Correspondence to: Vidhya Hariharan, PhD, AAD, 9500 W Bryn Mawr Ave, Suite 500, Rosemont, IL 60018.AAD9500 W Bryn Mawr AveSuite 500RosemontIL60018

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Tuesday 21 April 2020

Abstract

Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).

Le texte complet de cet article est disponible en PDF.

Key words : Clinical guidelines for psoriasis, dermatology, nonbiologic systemic, psoriasis, psoriasis guidelines, skin disease

Abbreviations used : AAD, ACR, AE, BB-UVB, BSA, BUN, CBC, CI, CYP3A4, FAE, FDA, GI, IL, NB-UVB, OPT, PASI, PUVA, RR, UV, UVA, UVB

Plan

	Funding sources: None.
	Conflicts of interest: Listed in text.
	IRB approval status: Not applicable.
	Reprints not available from the authors.

Export

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies - 21/04/20

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL